BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38216559)

  • 21. CRISPR-Based Technologies: Impact of RNA-Targeting Systems.
    Terns MP
    Mol Cell; 2018 Nov; 72(3):404-412. PubMed ID: 30388409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) RNAs in the Porphyromonas gingivalis CRISPR-Cas I-C System.
    Burmistrz M; Rodriguez Martinez JI; Krochmal D; Staniec D; Pyrc K
    J Bacteriol; 2017 Dec; 199(23):. PubMed ID: 28893837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Substrate generation for endonucleases of CRISPR/cas systems.
    Zoephel J; Dwarakanath S; Richter H; Plagens A; Randau L
    J Vis Exp; 2012 Sep; (67):. PubMed ID: 22986408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural Basis for the Canonical and Non-canonical PAM Recognition by CRISPR-Cpf1.
    Yamano T; Zetsche B; Ishitani R; Zhang F; Nishimasu H; Nureki O
    Mol Cell; 2017 Aug; 67(4):633-645.e3. PubMed ID: 28781234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-cleavage activity of Cas6b in crRNA processing of two different CRISPR-Cas systems in Methanosarcina mazei Gö1.
    Nickel L; Ulbricht A; Alkhnbashi OS; Förstner KU; Cassidy L; Weidenbach K; Backofen R; Schmitz RA
    RNA Biol; 2019 Apr; 16(4):492-503. PubMed ID: 30153081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phage-encoded anti-CRISPR enables complete evasion of type VI-A CRISPR-Cas immunity.
    Meeske AJ; Jia N; Cassel AK; Kozlova A; Liao J; Wiedmann M; Patel DJ; Marraffini LA
    Science; 2020 Jul; 369(6499):54-59. PubMed ID: 32467331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural Variation of Type I-F CRISPR RNA Guided DNA Surveillance.
    Pausch P; Müller-Esparza H; Gleditzsch D; Altegoer F; Randau L; Bange G
    Mol Cell; 2017 Aug; 67(4):622-632.e4. PubMed ID: 28781236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural Basis for Guide RNA Processing and Seed-Dependent DNA Targeting by CRISPR-Cas12a.
    Swarts DC; van der Oost J; Jinek M
    Mol Cell; 2017 Apr; 66(2):221-233.e4. PubMed ID: 28431230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Massively parallel CRISPRi assays reveal concealed thermodynamic determinants of dCas12a binding.
    Specht DA; Xu Y; Lambert G
    Proc Natl Acad Sci U S A; 2020 May; 117(21):11274-11282. PubMed ID: 32376630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9.
    Sternberg SH; Redding S; Jinek M; Greene EC; Doudna JA
    Nature; 2014 Mar; 507(7490):62-7. PubMed ID: 24476820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection.
    East-Seletsky A; O'Connell MR; Knight SC; Burstein D; Cate JH; Tjian R; Doudna JA
    Nature; 2016 Oct; 538(7624):270-273. PubMed ID: 27669025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells.
    Kleinstiver BP; Tsai SQ; Prew MS; Nguyen NT; Welch MM; Lopez JM; McCaw ZR; Aryee MJ; Joung JK
    Nat Biotechnol; 2016 Aug; 34(8):869-74. PubMed ID: 27347757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determining the Specificity of Cascade Binding, Interference, and Primed Adaptation
    Cooper LA; Stringer AM; Wade JT
    mBio; 2018 Apr; 9(2):. PubMed ID: 29666291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric DNA-RNA Guide RNA Designs.
    Lu S; Zhang Y; Yin H
    Methods Mol Biol; 2021; 2162():79-85. PubMed ID: 32926379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR-Cas9 Structures and Mechanisms.
    Jiang F; Doudna JA
    Annu Rev Biophys; 2017 May; 46():505-529. PubMed ID: 28375731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cas13d: A New Molecular Scissor for Transcriptome Engineering.
    Gupta R; Ghosh A; Chakravarti R; Singh R; Ravichandiran V; Swarnakar S; Ghosh D
    Front Cell Dev Biol; 2022; 10():866800. PubMed ID: 35433685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An active immune defense with a minimal CRISPR (clustered regularly interspaced short palindromic repeats) RNA and without the Cas6 protein.
    Maier LK; Stachler AE; Saunders SJ; Backofen R; Marchfelder A
    J Biol Chem; 2015 Feb; 290(7):4192-201. PubMed ID: 25512373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of single guide RNA transcription for efficient CRISPR/Cas-based genomic engineering.
    Ui-Tei K; Maruyama S; Nakano Y
    Genome; 2017 Jun; 60(6):537-545. PubMed ID: 28177825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A one-step platform for screening high-efficient and minimal off-target CRISPR/Cas13 crRNAs to eradicate SARS-CoV-2 virus for treatment of COVID-19 patients.
    Li PY; Li SQ; Gao SG; Dong DY
    Med Hypotheses; 2022 Feb; 159():110754. PubMed ID: 35002020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biogenesis pathways of RNA guides in archaeal and bacterial CRISPR-Cas adaptive immunity.
    Charpentier E; Richter H; van der Oost J; White MF
    FEMS Microbiol Rev; 2015 May; 39(3):428-41. PubMed ID: 25994611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.